<DOC>
	<DOCNO>NCT02765295</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , parallel-group trial . After 2-week run-in period , eligible patient , base randomization code keep sealed envelope , randomly assign receive usual care ( mucolytics and/or chest physiotherapy ) plus oxygen inahaltion ( 1 hr daily 12 consecutive month ) hydrogen inhalation ( 1 hr daily 12 consecutive month ) provide sponsor . At 3 month end-of-treatment , follow-up visit schedule patient .</brief_summary>
	<brief_title>Efficacy Safety Hydrogen Inhalation Bronchiectasis : A Randomized , Multi-center , Double-blind Study</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , parallel-group trial . After 2-week run-in period , eligible patient , base randomization code keep sealed envelope , randomly assign two groups.On basis usual care [ ambroxool ( 30mg thrice daily ) , N-acetylcysteine ( 0.2g thrice daily ) / serrapeptase ( 10mg thrice daily ) , carbocisteine ( 500mg thrice daily ) and/or chest physiotherapy ( 10 min , twice daily ) ] , patient randomize receive either hydrogen ( 66.7 % , 3L/min , 1 hr twice daily ) inhalation oxygen inhalation ( 3L/min , 1 hr twice daily ) via nasal canula 12 month . A follow-up visit month 3 follow end-of-treatment also schedule . The primary endpoint annual frequency bronchiectasis exacerbation . Hospital visit schedule baseline month 1 , 3 , 6 , 9 , 12 15 , respectively . At 3 month end-of-treatment , follow-up visit schedule patient .</detailed_description>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<criteria>Outpatients either gender , ex neversmokers , age 18 75 year Clinically stable bronchiectasis , define respiratory symptom lung function parameter exceed normal daily variation acute upper respiratory tract infection 4 consecutive week Patients history 2 bronchiectasis exacerbation ( BEs ) within previous 2 year Other unstable concomitant systemic illness ( i.e . coronary heart disease , recent cerebral stroke , severe uncontrolled hypertension , active gastric duodenal ulcer , uncontrolled diabetes , malignancy , hepatic renal dysfunction ) Concomitant asthma , allergic bronchopulmonary aspergillosis , active tuberculosis Concomitant chronic obstructive pulmonary disease predominant diagnosis Treatment inhale , oral systemic antibiotic within 4 week Type 2 respiratory failure need oxygen therapy noninvasive mechanical ventilation Females lactation pregnancy Poor understanding failure properly operate instrument Participation clinical trial within 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hydrogen</keyword>
	<keyword>Inhalation</keyword>
	<keyword>bronchiectasis</keyword>
</DOC>